TIAA Trust National Association Reduces Stake in Bristol Myers Squibb Company $BMY

TIAA Trust National Association cut its position in Bristol Myers Squibb Company (NYSE:BMY) by 9.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 108,305 shares of the biopharmaceutical company’s stock after selling 11,618 shares during the quarter. TIAA Trust National Association’s holdings in Bristol Myers Squibb were worth $5,013,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Trifecta Capital Advisors LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. REAP Financial Group LLC lifted its position in Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 428 shares during the period. Accent Capital Management LLC acquired a new stake in Bristol Myers Squibb during the 1st quarter worth approximately $33,000. CBIZ Investment Advisory Services LLC lifted its position in Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 231 shares during the period. Finally, GKV Capital Management Co. Inc. acquired a new stake in Bristol Myers Squibb during the 1st quarter worth approximately $36,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $45.96 on Tuesday. The stock has a fifty day moving average price of $45.32 and a 200 day moving average price of $46.76. The stock has a market cap of $93.55 billion, a PE ratio of 18.53, a P/E/G ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.4%. Bristol Myers Squibb’s payout ratio is currently 83.78%.

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a report on Tuesday, August 5th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Finally, Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $57.23.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.